Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Thirty Respiratory Limited
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06663176CT.gov Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bronchiectasis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Resp303 (this asset) | Thirty Respiratory Limited | P1/2 | CC · 45 |
| Ciprofloxacin | Centre Hospitalier Intercommunal Creteil | P4 | BBB |
| Azithromycin | Assiut University | P4 | BBB |
| Atorvastatin | University of Edinburgh | P4 | BB |
| Theophylline | The First Affiliated Hospital of Guangzhou Medical University | P4 | BB |
| Roflumilast | The University of Hong Kong | P3 | BB |
| Colistimethate | Centre Hospitalier Intercommunal Creteil | P3 | BB |
| Aztreonam Lysine | Gilead Sciences | P3 | BB |
| Ceftolozane | Sunshine Coast Hospital and Health Service | P4 | BB |
+42 more in the Bronchiectasis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Resp303 in Bronchiectasis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/resp303-bronchiectasis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →